Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director · CEO | August 16, 2024 | August 20, 2024 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | December 16, 2022 | December 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date August 16, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,520 |
Reported balance
After 2024-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-16 · Grant · Acquired 17,333 · Balance 173,520 F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. F2: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 218,302 |
Reported balance
After 2024-08-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-08-16 · Grant · Acquired 44,782 · Balance 218,302 F3: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. |
| Common StockSEC Table I · non-derivative | Direct | 186,555 |
Reported balance
After 2024-08-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-08-19 · Sale · Disposed 31,747 · Balance 186,555 F4: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
F2: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
F3: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
F4: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,854 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 74,739 · Balance 136,854 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
HERON THERAPEUTICS, INC. /DE/
Report date December 16, 2022 · Filed December 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,032 |
Reported balance
After 2022-12-16 transaction · row 1
1 source rowRow 1 · 2022-12-16 · Grant · Acquired 38,580 · Balance 52,032 F1: The shares were granted as restricted stock units which vest in full on December 16, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2032-12-16 | Direct | 77,160 |
Reported balance
After 2022-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-16 · Grant · Acquired 77,160 · Balance 77,160 F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on December 16, 2023.
F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,205 | $48.60 | $252,953.11 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,154 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.50 to $48.72, inclusive. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 13,908 | $48.98 | $681,244.44 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,359 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.73 to 49.72, inclusive. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 111,458 | $19.65 | $2,190,149.70 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 6,770 | $49.21 | $333,151.70 |
DisclosureSEC source: 0001209191-20-026617 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 29, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026617 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 15,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 15,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-026617 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 1,426 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001209191-20-025019 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426 Underlying: Common Stock · 1,426 shares Expires 2030-04-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in eight equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:04 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 38,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002597 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,110 Underlying: Common Stock · 38,110 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:04 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 138,304 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-20-002597 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,304 Underlying: Common Stock · 138,304 shares Expires 2030-01-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 6, 2021. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $25.02 | $0.00 |
DisclosureSEC source: 0001209191-19-061786 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2029-12-19 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-19-059526 · doc4.xml · derivative · entry 5 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 150,000 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the 600,000 shares originally subject to the stock option vested and became exercisable on March 15, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 28,256 | $51.32 | $1,450,097.92 |
DisclosureSEC source: 0001209191-19-059526 · doc4.xml · nonDerivative · entry 4 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.72 to $51.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 40,159 | $52.09 | $2,091,882.31 |
DisclosureSEC source: 0001209191-19-059526 · doc4.xml · nonDerivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,210 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.63 to $52.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 81,585 | $52.82 | $4,309,319.70 |
DisclosureSEC source: 0001209191-19-059526 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.64 to $53.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 150,000 | $19.65 | $2,947,500.00 |
DisclosureSEC source: 0001209191-19-059526 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053491 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,813 Underlying: Common Stock · 5,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,983 | $39.65 | $118,275.95 |
DisclosureSEC source: 0001209191-19-053491 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,954 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:23 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053491 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 21:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 120,208 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-19-053060 · doc4.xml · derivative · entry 6 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 120,208 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the 600,000 shares subject to the stock option vested and became exercisable on March 15, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 21:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 120,208 | $40.19 | $4,831,039.31 |
DisclosureSEC source: 0001209191-19-053060 · doc4.xml · nonDerivative · entry 4 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 21:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 120,208 | $19.65 | $2,362,087.20 |
DisclosureSEC source: 0001209191-19-053060 · doc4.xml · nonDerivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 21:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,792 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-19-053060 · doc4.xml · derivative · entry 5 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,208 Underlying: Common Stock · 29,792 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the 600,000 shares subject to the stock option vested and became exercisable on March 15, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 21:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 29,792 | $40.00 | $1,191,709.79 |
DisclosureSEC source: 0001209191-19-053060 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 21:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 29,792 | $19.65 | $585,412.80 |
DisclosureSEC source: 0001209191-19-053060 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 00:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $17.56 | $0.00 |
DisclosureSEC source: 0001209191-19-051413 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires 2029-10-01 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in three equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 00:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $17.56 | $0.00 |
DisclosureSEC source: 0001209191-19-051413 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-10-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 16:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001358403-19-000093 · wf-form4_156054265668848.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026842 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:55 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 219,298 | $0.00 Strike: $25.12 | $0.00 |
DisclosureSEC source: 0001209191-19-026842 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,298 Underlying: Common Stock · 219,298 shares Expires 2029-04-29 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| October 15, 2018 Filed Oct 24, 2018 20:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 23,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-027358 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,750 Underlying: Common Stock · 23,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning October 15, 2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning October 15, 2019. Read SEC document |
| October 15, 2018 Filed Oct 24, 2018 20:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option(right to buy) · Derivative | 95,000 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0000899243-18-027358 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2028-10-15 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on October 15, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:33 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001358403-18-000065 · wf-form4_152935397054916.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2019 Annual Meeting of stockholders. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 22:33 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-18-000655 · form4-04202018_030429.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2028-04-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:08 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 243,750 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001469 · form4-09082017_030906.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 243,750 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 16:36 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001358403-17-000093 · wf-form4_149755900162646.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2018 Annual Meeting of stockholders. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:36 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 243,750 | $0.00 Strike: $36.54 | $0.00 |
DisclosureSEC source: 0001415889-17-000405 · form4-03102017_050352.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 243,750 shares Expires 2027-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 8, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.